Sugi Predict

Sugi Predict / Compounds / SCHEMBL2928826

SCHEMBL2928826

SCHEMBL2928826

Cc1ccc(C=NO)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGF23 Q9GZV9 4/20 0.47
▸ ALDH1A1 P00352 5/20 0.45
▸ HPGD P15428 4/20 0.45
▸ NFE2L2 Q16236 2/20 0.44
▸ LMNA P02545 3/20 0.41
▸ GRIN2D O15399 2/20 0.41
▸ GRIN3B O60391 2/20 0.41
▸ GRIN1 Q05586 2/20 0.41
▸ GRIN2A Q12879 2/20 0.41
▸ GRIN2B Q13224 2/20 0.41
▸ GRIN2C Q14957 2/20 0.41
▸ GRIN3A Q8TCU5 2/20 0.41
▸ MAPT P10636 6/20 0.40
▸ HTT P42858 2/20 0.39
▸ RAB9A P51151 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13481435 1.00 FGF23 (0.47) FGF23ALDH1A1HPGDNFE2L2LMNA
SCHEMBL2928821 1.00 FGF23 (0.47) FGF23ALDH1A1HPGDNFE2L2LMNA
SCHEMBL18912171 0.82 NFE2L2 (0.46) NFE2L2LMNAGRIN2DGRIN3BGRIN1
SCHEMBL19626343 0.80 NFE2L2 (0.44) NFE2L2LMNAGRIN2DGRIN3BGRIN1
SCHEMBL17724986 0.80 NFE2L2 (0.44) NFE2L2LMNAGRIN2DGRIN3BGRIN1
SCHEMBL3175343 0.79 AMY1A (0.53) FGF23ALDH1A1HPGDLMNAMAPT
SCHEMBL3175339 0.79 AMY1A (0.53) FGF23ALDH1A1HPGDLMNAMAPT
SCHEMBL29761174 0.79 AMY1A (0.53) FGF23ALDH1A1HPGDLMNAMAPT
SCHEMBL1931856 0.79 GRIN2D (0.61) ALDH1A1NFE2L2LMNAGRIN2DGRIN3B
SCHEMBL29775672 0.79 GRIN2D (0.61) ALDH1A1NFE2L2LMNAGRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2767536-B1 Isoxazolo-pyridine derivatives HOFFMANN LA ROCHE (CH) 2015-09-02 — — EP disclosed
US-9073908-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2015-07-07 — — US disclosed
EP-2227467-B1 ISOXAZOLO-PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-12-31 — — EP disclosed
US-8877783-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-11-04 — — US disclosed
US-8877782-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-11-04 — — US disclosed
US-8846719-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-09-30 — — US disclosed
EP-2767536-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2014-08-20 — — EP disclosed
US-20130281690-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-24 — — US disclosed
US-20130274467-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 — — US disclosed
US-20130274469-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 — — US disclosed
US-20130274468-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 — — US disclosed
US-8518974-B2 Isoxazolo-pyridine derivatives Hoffmann-La Roche Inc (US) 2013-08-27 — — US disclosed
CN-101889010-B Isoxazolo-pyridine derivatives HOFFMANN LA ROCHE 2012-12-05 — — CN disclosed
CN-102757426-A Benzoisooxazolyl substituted thiazole compound, preparation method and application thereof INST MEDICINAL BIOTECHNOLOGY 2012-10-31 — — CN disclosed
US-20120184538-A1 ISOXAZOLO-PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2012-07-19 — — US disclosed
CN-101889010-A Isoxazolo-pyridine derivatives HOFFMANN LA ROCHE 2010-11-17 — — CN disclosed
EP-2227467-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-15 — — EP disclosed
WO-2009071476-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-11 — — WO disclosed
US-20090143371-A1 ISOXAZOLE-PYRIDINE DERIVATIVES ROCHE PALO ALTO LLC 2009-06-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143371-A1 ISOXAZOLE-PYRIDINE DERIVATIVES GABRA5, GABRA1, CHRNA5 FGF23 4328/4885ALDH1A1 938/4885HPGD 1489/4885
US-20130274468-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 FGF23 4415/4885ALDH1A1 955/4885HPGD 1443/4885
US-20130274467-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 FGF23 4415/4885ALDH1A1 955/4885HPGD 1443/4885
US-20130281690-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 FGF23 4415/4885ALDH1A1 955/4885HPGD 1443/4885
US-20130274469-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 FGF23 4415/4885ALDH1A1 955/4885HPGD 1443/4885
US-20120184538-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 FGF23 4415/4885ALDH1A1 955/4885HPGD 1443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.